PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to onset of 6-month composite confirmed disability progression compared to placebo ...

Detailed price information for Zenas Biopharma Inc (ZBIO-Q) from The Globe and Mail including charting and trades.

BARCELONA, Spain — A new phase 3 trial of ocrelizumab in primary progressive multiple sclerosis (PPMS) showed meaningful benefit in older patients and those with advanced disease — a first for this ...

A major international Phase III clinical trial, led by Queen Mary University of London, has found that ocrelizumab—a medication already prescribed to some patients with MS—significantly slows ...

The over-the-counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the brains of people with progressive forms of multiple sclerosis, according to new ...

Progressive multiple sclerosis encompasses both primary and secondary forms characterised by a sustained increase in neurological disability independent of acute relapses. Pathologically, it reflects ...

Lipoic acid (LA), an oral antioxidant supplement, was not associated with greater improvements in timed walking speed or other clinical outcomes in patients with progressive multiple sclerosis (MS) ...

Findings showed treatment with tolebrutinib did not significantly delay disability progression compared with placebo. A phase 3 study evaluating tolebrutinib for the treatment of primary progressive ...

Multiple sclerosis (MS) is one of the most common autoimmune diseases affecting the brain and spinal cord, with 2.9 million people estimated to be living with the disease worldwide. As MS is an ...

The proportion of patients with 12-week composite confirmed disability progression was 33 and 40%, respectively, with ocrelizumab and placebo. HealthDay News — For patients with primary progressive ...